Trial Profile
Benefit-risk of rivaroxaban 20 or 15 mg compared with vitamin K antagonists in patients with non- valvular atrial fibrillation: A cohort study in the French Nationwide Claims Database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
- 24 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management